Quantcast
Home > Quotes > COLL
x
COLL

Collegium Pharmaceutical, Inc. Common Stock (COLL) Quote & Summary Data

$16.4
*  
0.50
2.96%
Get COLL Alerts
*Delayed - data as of Oct. 19, 2018  -  Find a broker to begin trading COLL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    COLL After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / $ 18.79
1 Year Target
33
Today's High / Low
$ 17.1571 / $ 16.19
Share Volume
499,755
50 Day Avg. Daily Volume
446,804
Previous Close
$ 16.90
52 Week High / Low
$ 29.90 / $ 9.01
Market Cap
544,835,946
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.96
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.85

Intraday Chart

Shares Traded

Share Volume:
499,755
50 Day Avg. Daily Volume:
446,804

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.96

Trading Range

The current last sale of $16.40 is 82.02% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 17.1571 $ 29.90
 Low: $ 16.19 $ 9.01

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain. Our first product, Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. In April 2016, the U.S. Food and Drug Administration, or FDA, approved our new drug application, or NDA, filing for Xtampza for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Certain human abuse potential studies are included in the approved label, as well as data supporting the administration of the product as a sprinkle or administered through feeding tubes. In June 2016, we announced the commercial launch of Xtampza.  ... More ...  


Risk Grade

Where does COLL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 16.75
Open Date:
Oct. 19, 2018
Close Price:
$ 16.40
Close Date:
Oct. 19, 2018

Consensus Recommendation

Analyst Info